Healthy Skepticism Library item: 11789
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: news
Lohn M.
Minn. psychiatrist quits drug panel
Associated Press 2007 Oct 17
http://news.yahoo.com/s/ap/20071017/ap_on_re_us/doctors_drug_money
Full text:
ST. PAUL, Minn. – A Minnesota psychiatrist who received more than $350,000 in speaking and consulting fees from pharmaceutical companies will quit a panel that advises the state on drugs for low-income Medicaid patients.
Dr. John E. Simon said on Wednesday that he will resign because the organization that originally asked him to serve, the Minnesota Psychiatric Society, was “a little uncomfortable with the appearance of conflict of interest” posed by his panel membership.
Financial relationships between the drug industry and two panel members, including Simon, came to light when The Associated Press reviewed disclosure records filed by drug companies under a pioneering state law. Eli Lilly & Co. and other drug makers paid Simon more than $350,000 in honoraria and fees while he was serving on the Minnesota Medicaid Drug Formulary Committee. Another adviser who resigned last year got $78,000.
The Minnesota Department of Human Services is asking the panel members to sign off on a new policy requiring them to reveal “real or perceived” conflicts of interest, including honoraria, compensation, free travel or other perks from drug companies within the past five years.
They must abstain from voting on “any related matters that may come before the committee.”
Department spokeswoman Karen Smigielski said committee members are expected to approve the new policy before their next meeting on Tuesday.
The panel advises the human services agency on roughly $240 million worth of drugs for more than 200,000 patients, most of them mentally ill or disabled.
Simon said his work as a paid speaker didn’t influence his decisions on the committee. He joined the panel in mid-2004, and said he will resign when the Psychiatric Society picks another psychiatrist to replace him.
“I thought I did a good job of representing the patients of the Society and for the interest of psychiatric patients,” he said. “I have not heard otherwise.”
Linda Vukelich, the Minnesota Psychiatric Society’s executive director, praised Simon’s service but said there were concerns that he would have to sit out key votes under the new policy. She said the organization is grappling more broadly with the influence of business, including the drug industry, on medicine.
“It’s bigger than just one appointee or one situation,” she said.
Ethics experts have said the links between Minnesota’s drug advisers and the industry raise the possibility of similar arrangements in other states. But tracing the influence is difficult: Outside of Minnesota, only Vermont and Maine require drug companies to report payments to doctors for speeches, consulting and other services.
